Literature DB >> 11066075

CD44 is a potential target of amplification within the 11p13 amplicon detected in gastric cancer cell lines.

Y Fukuda1, N Kurihara, I Imoto, K Yasui, M Yoshida, K Yanagihara, J G Park, Y Nakamura, J Inazawa.   

Abstract

Classical cytogenetic approaches have revealed many of the chromosomal aberrations that may occur in gastric cancers (GC), although few alterations of specific genes have been identified so far. Genes that affect progression of this disease need to be identified if clinicians are to achieve optimal management of patients with GC. As the first step toward the cloning of gene(s) that may be involved in gastric carcinogenesis, we examined 25 GC cell lines for aberrations in DNA copy number to detect chromosomal gains and losses, as well as gene amplifications, by comparative genomic hybridization (CGH). Our CGH study revealed high-level amplifications in chromosomal regions that had been well defined in GC but also in sites that had not, including 3p24, 5p15, 11p11.2-14, 13q34, 15q26, Xp24, and Xq26-28. The minimal common region at 11p13, within the 11p11.2-14 amplicon, harbors the CD44 gene. Northern and Western blot analyses showed that an alternatively spliced form of CD44, with variant exons 8-10 (CD44E), was overexpressed in all cell lines bearing the 11p13 amplicon. However, cell adhesion activity was no greater in these lines than in cell lines without amplifications at the CD44 locus, suggesting that the major property of upregulated CD44 in these cases might be to transduce signals critically associated with growth and proliferation of the tumor cells. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11066075     DOI: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1047>3.0.co;2-e

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  10 in total

1.  A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers.

Authors:  Sana Yokoi; Kohichiroh Yasui; Fumiko Saito-Ohara; Katsumi Koshikawa; Toshihiko Iizasa; Takehiko Fujisawa; Takeo Terasaki; Akira Horii; Takashi Takahashi; Setsuo Hirohashi; Johji Inazawa
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

2.  Negative regulation of tumor suppressor p53 by microRNA miR-504.

Authors:  Wenwei Hu; Chang S Chan; Rui Wu; Cen Zhang; Yvonne Sun; Jun S Song; Laura H Tang; Arnold J Levine; Zhaohui Feng
Journal:  Mol Cell       Date:  2010-06-11       Impact factor: 17.970

3.  Reduced levels of ATF-2 predispose mice to mammary tumors.

Authors:  Toshio Maekawa; Toshie Shinagawa; Yuji Sano; Takahiko Sakuma; Shintaro Nomura; Koichi Nagasaki; Yoshio Miki; Fumiko Saito-Ohara; Johji Inazawa; Takashi Kohno; Jun Yokota; Shunsuke Ishii
Journal:  Mol Cell Biol       Date:  2006-12-22       Impact factor: 4.272

4.  Biology of SNU cell lines.

Authors:  Ja-Lok Ku; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

5.  GPC5 is a possible target for the 13q31-q32 amplification detected in lymphoma cell lines.

Authors:  Wei Yu; Jun Inoue; Issei Imoto; Yoshinobu Matsuo; Abraham Karpas; Johji Inazawa
Journal:  J Hum Genet       Date:  2003-04-29       Impact factor: 3.172

6.  Loss of fragile histidine triad and amplification of 1p36.22 and 11p15.5 in primary gastric adenocarcinomas.

Authors:  Yuan-Yuan Liu; Hai-Ying Chen; Man-Li Zhang; Dan Tian; Shibo Li; Ji-Yun Lee
Journal:  World J Gastroenterol       Date:  2012-09-07       Impact factor: 5.742

7.  Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.

Authors:  Jun Inoue; Takemi Otsuki; Akira Hirasawa; Issei Imoto; Yoshinobu Matsuo; Shiroh Shimizu; Masafumi Taniwaki; Johji Inazawa
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

8.  Structure and function of IQ-domain GTPase-activating protein 1 and its association with tumor progression (Review).

Authors:  Yan Wu; Yong-Chang Chen
Journal:  Biomed Rep       Date:  2013-11-20

9.  Identification of PDHX as a metabolic target for esophageal squamous cell carcinoma.

Authors:  Jun Inoue; Masahiro Kishikawa; Hitoshi Tsuda; Yasuaki Nakajima; Takahiro Asakage; Johji Inazawa
Journal:  Cancer Sci       Date:  2021-05-24       Impact factor: 6.716

10.  APIP, an ERBB3-binding partner, stimulates erbB2-3 heterodimer formation to promote tumorigenesis.

Authors:  Se-Hoon Hong; Won Jae Lee; Young Doo Kim; Hyunjoo Kim; Young-Jun Jeon; Bitna Lim; Dong-Hyung Cho; Won Do Heo; Doo-Hyun Yang; Chan-Young Kim; Han-Kwang Yang; Jin Kuk Yang; Yong-Keun Jung
Journal:  Oncotarget       Date:  2016-04-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.